Inactive Instrument

Portola Pharmaceuticals, Inc.

Stocks

US7370101088

Biotechnology & Medical Research

Portola Pharmaceuticals, Inc. Suspends Prior Guidance for Approximately 350 New Hospital Adds in 2020

Published on 05/11/2020 at 08:00 am EDT

S&P Capital IQ

PORTOLA PHARMACEUTICALS, INC.

-.--%

Portola Pharmaceuticals, Inc. suspending prior guidance for approximately 350 new hospital adds in 2020. With the uncertainty around the duration of COVID-19 impacts, Portola is suspending prior guidance provided during its fourth quarter 2019 call for approximately 350 new hospital adds in 2020.

Latest news about Portola Pharmaceuticals, Inc.

20-07-02	Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Biotechnology Select Industry Index	CI
20-07-02	Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P TMI Index	CI
20-07-02	Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Global BMI Index	CI
20-06-30	Alexion Pharmaceuticals, Inc. completed the acquisition of the remaining 96.6% stake in Portola Pharmaceuticals, Inc..	CI
20-06-17	Portola Pharmaceuticals, Inc. Receives Written Notice of Termination from Bayer AG	CI
20-05-11	Portola Pharmaceuticals, Inc. Suspends Prior Guidance for Approximately 350 New Hospital Adds in 2020	CI
20-05-11	Portola Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-05-04	Alexion Pharmaceuticals, Inc. entered into non-binding expression of interest to acquire remaining 96.6% stake in Portola Pharmaceuticals, Inc. for $1.4 billion.	CI
20-04-09	Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer, Inc. Aggress to Terminate the Collaboration and License Agreement Among the Parties	CI
20-04-07	Portola Pharmaceuticals, Inc. Announces the Establishment of Permanent J-Code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020	CI
20-03-16	Portola Pharmaceuticals, Inc. Announces Results Demonstrating Andexxa® Was Associated with Low Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds	CI
20-03-05	New Data Demonstrates Andexxa Can Provide Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors	CI
20-02-26	Portola Pharmaceuticals, Inc., Q4 2019 Earnings Call, Feb 26, 2020
20-02-26	Portola Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	CI
20-02-26	Portola Pharmaceuticals, Inc. Reports Impairment Charge for the Fourth Quarter Ended Dec. 31, 2019	CI

Chart Portola Pharmaceuticals, Inc.

Duration

Period

: Dynamic Chart

Company Profile

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Employees

Sector

Biotechnology & Medical Research

More about the company